Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®
23 Setembro 2024 - 3:00AM
Business Wire
New data presented by Teva at ECNP 2024* demonstrate
switching to UZEDY at four weeks after the last dose of
once-monthly Perseris® (RBP-7000) provided the most comparable
pharmacokinetic (PK) profile based on relevant simulations, with
comparable doses identified.
Perseris manufacturer announced in July 2024 the
discontinuation of its commercialization.
Teva already presented in June 2024 data informing clinical
strategies for switching patients to UZEDY from a once-monthly
intramuscular injection of Invega Sustenna® (paliperidone
palmitate)**.
Richard Malamut, Chief Medical Officer of Medincell said: “We
are delighted to see that our partner is fully committed to
supporting healthcare providers in implementing effective switching
strategies to UZEDY, which offers several key differentiating
features compared to other risperidone or paliperidone palmitate
formulations: no loading doses or oral supplementation at
initiation, flexible dosing intervals of either one or two months,
subcutaneous administration, ready-to-use prefilled
syringe.”
About additional results from the Advance study on the
utilization of long-acting injectable antipsychotics, which were
also reported by Teva at ECNP 2024, Richard Malamut said: “It is
encouraging to see that most of the factors raised by patients with
Schizophrenia, their caregivers, and healthcare providers regarding
use of a long-acting injectable antipsychotic can be effectively
addressed with UZEDY.”
ACCESS HERE THE COMPLETE PRESS
RELEASE
* 37th Annual European College of Neuropsychopharmacology (ECNP)
Congress - September 21-24, 2024, Milan, Italy. www.ecnp.eu **
Medincell’s press release, June 3rd, 2024:
https://www.medincell.com/wp-content/uploads/2024/06/PR_MDC_Elevate2024_EN_vf.pdf
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical
licensing company developing long-acting injectable drugs in many
therapeutic areas. Our innovative treatments aim to guarantee
compliance with medical prescriptions, to improve the effectiveness
and accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO® technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY® (BEPO® technology is
licensed to Teva under the name SteadyTeq™). We collaborate with
leading pharmaceutical companies and foundations to improve global
health through new treatment options. Based in Montpellier,
Medincell currently employs more than 140 people representing more
than 25 different nationalities.
UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals
www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240922034604/en/
David Heuzé Head of Corporate and Financial
Communications, and ESG david.heuze@Medincell.com / +33 (0)6 83 25
21 86
Grace Kim Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023
Nicolas Mérigeau/ Arthur Rouillé Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Louis-Victor Delouvrier/Alban Dufumier Investor Relations
France Medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025